$GRTX
Galera Therapeutics Inc
PRICE
$2.28 ▲3.636%
Extented Hours
VOLUME
844,345
DAY RANGE
2.1 - 2.3
52 WEEK
1.12 - 2.68
Join Discuss about GRTX with like-minded investors
@soheil.n #StockTraders.NET
TTM Watchlist: $ENSC reactionary, its multiday runner by now. 7 mil float. $BVXV potential for 30-40c fade today $GRTX long bias 4,70 target $SOPA multiday runner $KXIN if gets higher Current cycle: Strong but mixed performances split across two themes.
147 Replies 7 👍 6 🔥
@Baljit123 #StockTraders.NET
Long Watchlist 1. BFRI there are still many shorts trapped but I think this wil be pulling back for a few days so may give some good intraday bounces but a better short and probably choppy 2. SOPA still holding 10 line tighter range day with the pivots so may not get as much movement 3. IINN had Green day yesterday low float basing around the 3 line on the daily watch for ssome volume and catalyst to get it moving again 4. GRTX ran yesterday at the close I was $.20 line is the mid pivot look for potential bounce on 4.20 and move back to 5 maybe 5.50/6 if volume comes in 5. VLON looks like getting ready to make a move on the daily low float bio tech these have been moving lately VLON, IPSC, LGVN watching for moves together Any new hot chicks
115 Replies 14 👍 12 🔥
@maletone #StockTraders.NET
lets hope they keep $GRTX for tomorrow... but likely will be back under 4.40 by 8 PM
91 Replies 13 👍 11 🔥
@soheil.n #StockTraders.NET
TTM Watchlist: $ARDS 10 mil float, weaker volumes in pre market. $RELI nano floaterb high volume, On watch for "count the cards" approach, to spot potential float rotation long setups if bases. $PPSI $BFRI Further upside in play. $SOPA multiday runner potential. $GRTX
68 Replies 6 👍 15 🔥
@Baljit123 #StockTraders.NET
GRTX - Looking for a morning pop and FAIL to short. Let it do its thing first then I will attack QNRX - Same plan as above. Let it pop toward 3.00 and fail then we will attack. Or if it tanks out of the open will use VWAP as a guide for a nail and bail short ARDS - Looking for a pop toward VWAP / 5.00 / 5.20 to short. This is ETB so must be VERY VERY CAREFUL. Do not over trade it and do not over stay it SOPA - 2 potential trades. Looking to scale in 10% of the time 13.00 / 13.50 / 14.00. Remain 30% size and add only on confirm OR short when it goes red! RELI - HOT CHICK. Let it do its thing. This has SSR so it can trap and zombie. So I am ignoring it for now!!!! CANF - Low hanging fruit. 2.00 / 2.20 lines to short https://myinvestingclub.com/trading/how-to-scale-into-the-watch-list-when-to-use-max-full-size-when-trading-30-rule-watch-list/
111 Replies 11 👍 14 🔥
Key Metrics
Market Cap
94.23 M
Beta
0.85
Avg. Volume
796.60 K
Shares Outstanding
42.83 M
Yield
0%
Public Float
0
Next Earnings Date
Next Dividend Date
Company Information
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera's second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA.
Website: galeratx.com
HQ: ,
Related News